Researchers from the Friedrich Miescher Institute, EPFL and collaborators mapped a latent cereblon molecular-glue interaction space by combining high-throughput protein-complementation screening with AI-based protein-surface mimicry. GluePCA identified approximately 210 zinc-finger domains that bind CRBN–pomalidomide,…
Elicera Therapeutics appointed Johan Liwing as chief executive officer effective September 1, 2026. He succeeds co-founder Jamal El-Mosleh, who will remain employed through October 31 to provide an orderly handover. The transition follows Elicera’s…
BioMarin agreed to acquire privately held Alesta Therapeutics for $275 million upfront in cash plus up to $215 million in development and regulatory milestones. The transaction is centered on ALE1, an oral small molecule…
Amylyx reported that avexitide met the FDA-agreed primary endpoint in the 78-participant Phase III LUCIDITY trial for post-bariatric hypoglycemia following Roux-en-Y gastric bypass. Once-daily subcutaneous avexitide reduced the composite rate of Level 2 and…
Abcuro closed a $66 million Series D financing to fund a new, potentially registrational study of ulviprubart in people with less severe inclusion-body myositis (IBM). New Leaf Venture Partners led the round, with Rock…
Valion Bio disclosed that Michael K. Handley was terminated as chief executive officer effective August 16, 2026. On the same date, Lisa Wolf was appointed chief operating officer while retaining her chief financial officer…
University of Wisconsin–Madison investigators used a genome-wide CRISPR screen to identify endogenous cellular barriers to nonviral genome editing. Among 19,114 genes, six high-confidence negative regulators improved editing across delivery formats, loci and payloads when…
A multi-institutional consortium led by UCSF investigators reported a virus-like-particle (VLP) toolkit for high-efficiency CRISPR engineering and pooled screening in primary human monocytes, macrophages and dendritic cells while preserving viability and innate responsiveness. The…
Shanghai Henlius Biotech and Sandoz expanded their biosimilars relationship through a framework covering up to ten proposed monoclonal-antibody or antibody-drug-conjugate biosimilar products or components. Initial terms cover three assets — cetuximab biosimilar HLX05-N, evolocumab…
Fulcrum Therapeutics and privately held Slate Medicines entered a definitive all-stock merger centered on Slate’s migraine pipeline and a concurrent $245 million private placement led by Frazier Life Sciences. The combined company is expected…
